the road to hrct evaluation of pediatric diffuse lung diseases.part 2

28
The road to HRCT evaluation of Dr/Ahmed Bahnassy Consultant Radiologist Riyadh Military Hospital

Upload: ahmed-bahnassy

Post on 07-May-2015

1.177 views

Category:

Health & Medicine


2 download

DESCRIPTION

part 2 of step by step evaluation of pediatric diffuse lung diseases.

TRANSCRIPT

Page 1: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

The road to HRCT evaluation of

Dr/Ahmed Bahnassy

Consultant Radiologist

Riyadh Military Hospital

Page 2: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Causes of chILD• Infectious • Aspiration

(GORD)• Environmental

(hypersensitivity pneumonitis)

• Drug-induced • Neoplastic

diseases (&LCH)

• Lymphoproliferative disorders (including HIV)

• Metabolic disorders

• Surfactant disorders

• Neurocutaneous syndromes

• Idiopathic pulm hemosidrosis

• Infectious • Aspiration

(GORD)• Environmental

(hypersensitivity pneumonitis)

• Drug-induced • Neoplastic

diseases (&LCH)

Page 3: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Causes of chILD cont….

• Collagen vascular disease

• Pulmonary vasculitis syndromes

• Radiation-induced

• Amyloidosis• Graft-versus-

host disease

• ARDS (recovering phase)

• Hypereosinophilic syndromes

• Pulmonary veno-occlusive disease

• Sarcoidosis• With chronic

liver, kidney, bowel diseases

• Lymphoproliferative disorders (including HIV)

• Metabolic disorders• Surfactant disorders• Neurocutaneous

syndromes

• Idiopathic pulm hemosidrosis

Page 4: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Causes of ILD

Page 5: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2
Page 6: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2
Page 7: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Between Adults and ChILD

NSIP

ILD

Page 8: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

DIP

LIP

Page 9: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2
Page 10: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Neuroendocrine cell hyperplasia of infancy (NEHI)

Ground Glass opacity primarily affecting the middle and lingular lobes

Page 11: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

NEHI

• Another typical example of right middle lobe ,and left lingular GGO.

Page 12: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Surfactant Metabolism Dysfunction

• Surfactant is a complex mixture of phospholipids

and proteins (SP-A, -B, -C and -D)& ABCA3.

• ABCA3 an ATP-binding transporter Of lipids.

(chILD) due to ABCA3 gene mutations

Diffuse GG opacity with variableIntelobular septal thickening

Page 13: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Nonspecific interstitial pneumonitis

Bilateral scattered middle zonal GGOBi basilar consolidations.Bronchial dilatation.

HRCT shows a mosaicperfusion pattern and multiple bilateral linear densities

Page 14: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

PIG..Pulmonary interstitial Glycogenosis

• GGO

• Interlobular septal thickening.

• Reticular changes.

• Posterior cysts.

Page 15: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

BOOP• Diffuse

nodules.

• Mild intralobular septal thickening.

• Patchy GGO.

Page 16: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Hypersensitivity pneumonitis

• Ground Glass and nodular like opacities in lung bases.

Page 17: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Eosinophilic pneumonia

• Reversed Halo sign

• Right peripheral mid-zonal GGO

Page 18: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Pulmonary alveolar proteinosis

• GGO

• +

• Interlobular septal thickening

• =

• Crazy-paving pattern.

Page 19: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Bronchopulmonary Dysplasia septal thickening,

parenchymal bands and multiple hyperlucent areas.

Repeated HRCT at the age of 2 years shows a mosaic pattern andsome residual parenchymal bands

Page 20: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Parenchymal bands in BPD

Page 21: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Bronchial asthma

Normal

Expiratory scan revealed severeAir trapping

Page 22: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Hemosiderosis

ground-glass attenuation due to pulmonary hemorrhage

Page 23: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Langerhans cell histiocytosis

thick- and thin-walled cysts;few micronodules also seen

pulmonary cystic lesions, some located subpleurally, andbilateral pneumothoraces

Bizarre shaped

Page 24: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Lympngiomatosis

Prominent diffuse smooth septal thickening, bronchovascularbundles and ground-glass attenuation

Consider vascular/lymphatic cause

Page 25: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

Lesson learned

Most HRCT features are non-specific,

but when related to the clinical findings, they can suggest the proper diagnosis and obviate biopsy.

Page 26: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2

A new classification system for pediatricinterstitial lung disease evolved out of the recognitionthat clinical setting is an important considerationin the diagnosis of pediatric ILD and thatcombined clinical, imaging, and pathological correlationis a more powerful diagnostic tool, thanany one single component.

This new pediatric interstitial lung disease classification system was validated for infants and very young children in a retrospective review of 186 lung biopsies done

between 1999 and 2004 with accompanying clinical histories and images from children under age 2 contributed by 11 pediatric institutions in North America.

Based on this new classification system, ChILD is classified into three main groups: (1) disorders of infancy; (2) other categories

(not specific to infancy); and (3)unclassifiable.

Page 27: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2
Page 28: The road to HRCT evaluation of pediatric diffuse lung diseases.part 2